Novo Nordisk buys university spinout Ziylo — adding a potential remedy for hypoglycemia to its diabetes pipeline
The busy R&D group at Novo Nordisk is adding an early research program to its arsenal of diabetes therapies.
In a “staged acquisition” that could be worth up to $800 million — with an upfront that the companies aren’t disclosing — Novo has gained full rights to some glucose binding molecules developed by Ziylo, a Bristol, UK-based biotech whose team will now work directly with Novo researchers in both Oxford and Copenhagen.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.